Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal

Current Psychiatry Reports

Volumn 18, Issue 5, 2016, Pages

  Cooper, Ziva D ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Adverse effects; Cannabis; Dependence; K2; Spice; Synthetic cannabinoid; Withdrawal

Indexed keywords

CANNABINOID; SYNTHETIC CANNABINOID; UNCLASSIFIED DRUG; STREET DRUG;

ADULT; CANNABIS USE; CONTROLLED STUDY; DRUG DETOXIFICATION; DRUG INTOXICATION; DRUG MECHANISM; DRUG SCREENING; FEMALE; HUMAN; MALE; PUBLIC HEALTH; REVIEW; TREND STUDY; UNITED STATES; SUBSTANCE WITHDRAWAL SYNDROME;

CANNABINOIDS; HUMANS; STREET DRUGS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84963740710     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-016-0694-1     Document Type: Review

References (64)

1. Wehrman J. Fake marijuana spurs more than 2,500 calls to U.S. poison centers this year alone. Alexandra: American Association of Poison Control Centers; 2010.
2. United States Drug Enforcement Administration. Schedules of controlled substances: placement of five synthetic cannabinoids into Schedule I, 21 CFR Part 1308 [Docket No. DEA-345]. Fed Regist. 2012;77:12508–14.
3. United States Drug Enforcement Administration. DEA makes three more “fake pot” drugs temporarily illegal today. Washington: United States Department of Justice; 2013.
4. United States Drug Enforcement Administration. DEA news: huge synthetic drug takedown. Washington: United States Department of Justice; 2014.
5. United States Drug Enforcement Administration. Schedules of controlled substances: temporary placement of the synthetic cannabinoid MAB-CHMINACA into Schedule I. United States Department of Justice, Washington, D.C. 2015. Retrieved on November 11, 2015. http://www.deadiversion.usdoj.gov/fed_regs/rules/2015/fr0916_2.htm
6. Law R, Schier C, Martin A, Chang A, Wolkin A, Centers for Disease Control (CDC). Notes from the field: increase in reported adverse health effects related to synthetic cannabinoid use—United States, January–May 2015. MMWR Morb Mortal Wkly Rep. 2015;64:618–9.
7. Kasper AM, Ridpath AD, Arnold JK, Chatham-Stephens K, Morrison M, Olayinka O, et al. Severe illness associated with reported use of synthetic cannabinoids—Mississippi, April 2015. MMWR Morb Mortal Wkly Rep. 2015;64:1121–2.
8. New York City Department of Health and Mental Hygiene. Increase in synthetic cannabinoid (marijuana)-related adverse events and emergency department visits. April, 2015. http://www.nyc.gov/html/doh/downloads/pdf/ah/marijuana-alert.pdf. Accessed 20 November 2015.
9. New York City Department of Health and Mental Hygiene. Increase in synthetic cannabinoid (K2)-related adverse events and emergency department visits. September 2015. https://a816-health30ssl.nyc.gov/sites/nychan/Lists/AlertUpdateAdvisoryDocuments/Synthetic%20cannabinoids-HAN-advisory_Summer%202015%20-penultimate8.pdf. Accessed 20 November 2015.
10. Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014.
11. Atwood BK, Huffman J, Straiker A, Mackie K. JWH018, a common constituent of ‘Spice’ herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol. 2010;60:585–93.
12. Atwood BK, Lee D, Straiker A, Widlanski TS, Mackie K. CP47,497-C8 and JWH073, commonly found in ‘Spice’ herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists. Eur J Pharmacol. 2011;659:139–45.
13. Chin CN, Murphy JW, Huffman JW, Kendall DA. The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. J Pharmacol Exp Ther. 1999;291:837–44.
14. Hsieh C, Brown S, Derleth C, Mackie K. Internalization and recycling of the CB1 cannabinoid receptor. J Neurochem. 1999;73:493–501.
15. Nguyen PT, Schmid CL, Raehal KM, Selley DE, Bohn LM, Sim-Selley LJ. β-Arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner. Biol Psychiatry. 2012;71:714–24.
16. Rodriguez JS, McMahon LR. JWH-018 in rhesus monkeys: differential antagonism of discriminative stimulus, rate-decreasing, and hypothermic effects. Eur J Pharmacol. 2014;740:151–9.
17. Tai S, Hyatt WS, Gu C, Franks LN, Vasiljevik T, Brents LK, et al. Repeated administration of phytocannabinoid Δ9-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner. Pharmacol Res. 2015;102:22–32.
18. González S, Cebeira M, Fernández-Ruiz J. Cannabinoid tolerance and dependence: a review of studies in laboratory animals. Pharmacol Biochem Behav. 2005;81:300–18.
19. Wiley JL, Compton DR, Dai D, Lainton JA, Phillips M, Huffman JW, et al. Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J Pharmacol Exp Ther. 1998;285:995–1004.
20. Jarbe TU, Deng H, Vadivel SK, Makriyannis A. Cannabinergic aminoalkylindoles, including AM678=JWH018 found in ‘Spice’, examined using drug (delta(9)-tetrahydrocannabinol) discrimination for rats. Behav Pharmacol. 2011;22:498–507.
21. Ginsburg BC, Schulze DR, Hruba L, McMahon LR. JWH-018 and JWH-073: delta-tetrahydrocannabinol-like discriminative stimulus effects in monkeys. J Pharmacol Exp Ther. 2012;340:37–45.
22. Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: mechanism underlying greater toxicity? Life Sci. 2013;97:45–54. A comprehensive review of preclinical studies that demonstrate pharmacological differences between synthetic cannabinoids and THC that contribute to their enhanced toxic effects.
23. Marusich JA, Huffman JW. Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids. Life Sci. 2014;97:55–63.
24. Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, et al. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol. 2012;83:952–61.
25. Auwarter V, Dresen S, Weinmann W, Muller M, Putz M, Ferreiros N. ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom. 2009;44:832–7.
26. Renner KE. Delay of reinforcement: a historical review. Psychol Bull. 1964;61:341–61.
27. de Villiers P. Choice in concurrent schedules and a quantitative formulation of the law of effect. Handbook of Operant Behavior. 1977;233–287.
28. Mello NK, Lukas SE, Bree MP, Mendelson JH. Progressive ratio performance maintained by buprenorphine, heroin and methadone in Macaque monkeys. Drug Alcohol Depend. 1977;21(2):81–97.
29. Winger G, Hursh SR, Casey KL, Woods JH. Relative reinforcing strength of three N-methyl-D-aspartate antagonists with different onsets of action. J Pharmacol Exp Ther. 2002;301(2):690–7.
30. Burkey TH, Quock RM, Consroe P, Roeske WR, Yamamura HI. Delta 9 tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain. Eur J Pharmacol. 1997;323:R3–4.
31. Hruba L, McMahon LR. The cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus effects in rhesus monkeys. Eur J Pharmacol. 2014;727:35–42.
32. Hovav E, Weinstock M. Temporal factors influencing the development of acute tolerance to opiates. J Pharmacol Exp Ther. 1987;242:251–6.
33. Baumann MH, Solis E, Watterson LR, Marusich JA, Fantegrossi WE, Wiley JL. Bath salts, Spice, and related designer drugs: the science behind the headline. J Neurosci. 2014;34:15150–8.
34. Seely KA, Patton AL, Moran CL, Womack ML, Prather PL, Fantegrossi WE, et al. Forensic investigation of K2, Spice, and “bath salt” commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci Int. 2013;233:416–22. This article describes findings from a forensic analyses of 3000 drug-related products confiscated over a three year period. This analysis describes the prevalence of synthetic cannabinoid compounds in confiscated items, and the wide range of compounds detected within and across products.
35. Fattore L, Fratta W. Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci. 2011;5:60.
36. Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction. 2013;108:534–44. This article provides a comprehensive description of acute toxic effects due to confirmed synthetic cannabinoid use including onset, duration, and severity of symptom, and symptom management as a function of specific synthetic cannabinoids detected by serum and urine toxicology.
37. Meijer KA, Russo RR, Adhvaryu DV. Smoking synthetic marijuana leads to self-mutilation requiring bilateral amputations. Orthopedics. 2014;37:391–4.
38. Jinwala FN, Gupta M. Synthetic cannabis and respiratory depression. J Child Adolesc Psychopharmacol. 2012;22:459–62.
39. Mir A, Obafemi A, Young A, Kane C. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics. 2011;128:1622–7.
40. Davis C, Boddington D. Teenage cardiac arrest following abuse of synthetic cannabis. Heart Lung Circ. 2015;24:e162–3.
41. Bhanushali GK, Jain G, Fatima H, Leisch LJ, Thomley-Brown D. AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol. 2013;8:523–6.
42. Hopkins CY, Gilchrist BL. A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids. J Emerg Med. 2013;45:544–6.
43. Bick BL, Szostek JH, Mangan TF. Synthetic cannabinoid leading to cannabinoid hyperemesis syndrome. Mayo Clin Proc. 2014;89:1168–9.
44. Ukaigwe A, Karmacharya P, Donato A. A gut gone to pot: a case of cannabinoid hyperemesis syndrome due to K2, a synthetic cannabinoid. Case Rep Emerg Med. 2014;2014:167098.
45. Sevinc MM, Kinaci E, Bayrak S, Yardimci AH, Cakar E, Bektaş H. Extraordinary cause of acute gastric dilatation and hepatic portal venous gas: chronic use of synthetic cannabinoid. World J Gastroenterol. 2015;21:10704–8.
46. Sweeney B, Talebi S, Toro D, Gonzalez K, Menoscal JP, Shaw R, et al. Hyperthermia and severe rhabdomyolysis from synthetic cannabinoids. Am J Emerg Med. 2015. doi:10.1016/j.ajem.2015.05.052.
47. Takematsu M, Hoffman RS, Nelson LS, Schechter JM, Moran JH, Wiener SW. A case of acute cerebral ischemia following inhalation of a synthetic cannabinoid. Clin Toxicol. 2014;52:973–5.
48. Lapoint J, James LP, Moran CL, Nelson LS, Hoffman RS, Moran JH. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol. 2011;49:760–4.
49. Schep LJ, Slaughter RJ, Hudson S, Place R, Watts M. Delayed seizure-like activity following analytically confirmed use of previously unreported synthetic cannabinoid analogues. Hum Exp Toxicol. 2015;34:557–60.
50. Durand D, Delgado LL, de la Parra-Pellot DM, Nichols-Vinueza D. Psychosis and severe rhabdomyolysis associated with synthetic cannabinoid use: a case report. Clin Schizophr Relat Psychoses. 2015;8:205–8.
51. Ustundag MF, Ozhan Ibis E, Yucel A, Ozcan H. Synthetic cannabis-induced mania. Case Rep Psychiatry. 2015. doi:10.1155/2015/310930.
52. Rodgman CJ, Verrico CD, Worthy RB, Lewis EE. Inpatient detoxification from a synthetic cannabinoid and control of postdetoxification cravings with naltrexone. Prim Care Companion CNS. 2014;16:4.
53. Macfarlane V, Christie G. Synthetic cannabinoid withdrawal: a new demand on detoxification services. Drug Alcohol Rev. 2015;34:147–53. This article reports on demographics of a population presenting for treatment for problematic synthetic cannabinoid use, withdrawal symptoms, and treatment strategies.
54. Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R, Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of “spice gold”. Dtsch Arztebl Int. 2009;106:464–7.
55. Nacca N, Vatti D, Sullivan R, Sud P, Su M, Marraffa J. The synthetic cannabinoid withdrawal syndrome. J Addict Med. 2013;7:296–8.
56. Sampson CS, Bedy SM, Carlisle T. Withdrawal seizures seen in the setting of synthetic cannabinoid abuse. Am J Emerg Med. 2015;33:1712.e3.
57. Cooper ZD, Haney M. Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. Addict Biol. 2008;13:188–95.
58. Oluwabusi OO, Lobach L, Akhtar U, Youngman B, Ambrosini PJ. Synthetic cannabinoid-induced psychosis: two adolescent cases. J Child Adolesc Psychopharmacol. 2012;22:393–5.
59. Hu X, Primack BA, Barnett TE, Cook RL. College students and use of K2: an emerging drug of abuse in young persons. Subst Abuse Treat Prev Policy. 2011;6:16.
60. Vandrey R, Dunn KE, Fry JA, Girling ER. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend. 2012;120:238–41.
61. Kelly BC, Wells BE, Pawson M, Leclair A, Parsons JT, Golub SA. Novel psychoactive drug use among younger adults involved in US nightlife scenes. Drug Alcohol Rev. 2013;32:588–93.
62. Spaderna M, Addy PH, D’Souza DC. Spicing things up: synthetic cannabinoids. Psychopharmacology. 2013;228:525–40.
63. Winstock AR, Barratt MJ. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend. 2013;131:106–11.
64. Haney M, Cooper ZD, Bedi G, Vosburg SK, Comer SD, Foltin RW. Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology. 2013;38:1557–65.